English
简体中文
Total: £ 56.28
Published Date: 2025-08-08 | Pages: 107 | Tables: 101 | Pharma & Healthcare
The global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size was US$ 410 million in 2024 and is forecast to a readjusted size of US$ 521 million by 2031 with a CAGR of 3.3% during the forecast period 2025-2031.
By 2025, the evolving U.S. tariff policy is poised to inject considerable uncertainty into the global economic landscape. This report delves into the latest U.S. tariff measures and the corresponding policy responses across the globe, evaluating their impacts on Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market competitiveness, regional economic performance, and supply chain configurations.
Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine is a biological product designed to prevent and control PRRS, a highly contagious viral disease that affects pigs. The vaccine works by stimulating the pig's immune system to produce a protective response against the PRRS virus, thereby reducing reproductive failures such as abortions and stillbirths in sows, as well as respiratory illness and mortality in piglets and growing pigs. PRRS vaccines are typically classified into modified live vaccines (MLVs) and inactivated vaccines, and they play a critical role in improving herd health and productivity in the swine industry worldwide.
The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.
Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.
The global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
China Animal Husbandry Co., Ltd.
Boehringer Ingelheim
MSD Animal Health
Sinopharm Animal Health
Ceva
Ruipu Biological
Qilu Animal Health
Dahuanong
CAVAC
Komipharm
Agrovet
Bioveta
Jinyu
Phibro Animal Health
Tiankang
Zoetis
Yongshun Biological
Pulike Biological
By Type: (Dominant Segment vs High-Margin Innovation)
Live vaccines
Inactivated vaccines
By Application: (Core Demand Driver vs Emerging Opportunity)
Government bidding
Market sales
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., China Animal Husbandry Co., Ltd. in Europe)
- Emerging Product Trends: Live vaccines adoption vs. Inactivated vaccines premiumization
- Demand-Side Dynamics: Government bidding growth in China vs. Market sales potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Inactivated vaccines in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Market sales in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Live vaccines dominance in Europe vs. Inactivated vaccines demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Scope
1.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Type
1.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020 & 2024 & 2031)
1.2.2 Live vaccines
1.2.3 Inactivated vaccines
1.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Application
1.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Government bidding
1.3.3 Market sales
1.4 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Estimates and Forecasts (2020-2031)
1.4.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2020-2025)
2.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Region (2020-2025)
2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size and Prospective (2020-2031)
2.4.2 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size and Prospective (2020-2031)
2.4.3 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size and Prospective (2020-2031)
2.4.4 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Historic Market Review by Type (2020-2025)
3.1.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025)
3.1.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (2020-2025)
3.1.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Type (2020-2025)
3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Forecast by Type (2026-2031)
3.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Forecast by Type (2026-2031)
3.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price Forecast by Type (2026-2031)
3.3 Different Types Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Representative Players
4 Global Market Size by Application
4.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Historic Market Review by Application (2020-2025)
4.1.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025)
4.1.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Application (2020-2025)
4.1.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Application (2020-2025)
4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Forecast by Application (2026-2031)
4.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Forecast by Application (2026-2031)
4.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Application
5 Competition Landscape by Players
5.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Players (2020-2025)
5.2 Global Top Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Players by Revenue (2020-2025)
5.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine as of 2024)
5.4 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Product Type & Application
5.7 Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company
6.1.1.1 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025)
6.1.1.2 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025)
6.1.2 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Type (2020-2025)
6.1.3 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Application (2020-2025)
6.1.4 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company
6.2.1.1 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025)
6.2.1.2 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025)
6.2.2 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Type (2020-2025)
6.2.3 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Application (2020-2025)
6.2.4 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company
6.3.1.1 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025)
6.3.1.2 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025)
6.3.2 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Type (2020-2025)
6.3.3 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Application (2020-2025)
6.3.4 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company
6.4.1.1 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025)
6.4.1.2 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025)
6.4.2 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Type (2020-2025)
6.4.3 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Breakdown by Application (2020-2025)
6.4.4 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Major Customer
6.4.5 Japan Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 China Animal Husbandry Co., Ltd.
7.1.1 China Animal Husbandry Co., Ltd. Company Information
7.1.2 China Animal Husbandry Co., Ltd. Business Overview
7.1.3 China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.1.4 China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.1.5 China Animal Husbandry Co., Ltd. Recent Development
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Information
7.2.2 Boehringer Ingelheim Business Overview
7.2.3 Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.2.5 Boehringer Ingelheim Recent Development
7.3 MSD Animal Health
7.3.1 MSD Animal Health Company Information
7.3.2 MSD Animal Health Business Overview
7.3.3 MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.3.4 MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.3.5 MSD Animal Health Recent Development
7.4 Sinopharm Animal Health
7.4.1 Sinopharm Animal Health Company Information
7.4.2 Sinopharm Animal Health Business Overview
7.4.3 Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.4.5 Sinopharm Animal Health Recent Development
7.5 Ceva
7.5.1 Ceva Company Information
7.5.2 Ceva Business Overview
7.5.3 Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.5.5 Ceva Recent Development
7.6 Ruipu Biological
7.6.1 Ruipu Biological Company Information
7.6.2 Ruipu Biological Business Overview
7.6.3 Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.6.5 Ruipu Biological Recent Development
7.7 Qilu Animal Health
7.7.1 Qilu Animal Health Company Information
7.7.2 Qilu Animal Health Business Overview
7.7.3 Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.7.5 Qilu Animal Health Recent Development
7.8 Dahuanong
7.8.1 Dahuanong Company Information
7.8.2 Dahuanong Business Overview
7.8.3 Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.8.5 Dahuanong Recent Development
7.9 CAVAC
7.9.1 CAVAC Company Information
7.9.2 CAVAC Business Overview
7.9.3 CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.9.4 CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.9.5 CAVAC Recent Development
7.10 Komipharm
7.10.1 Komipharm Company Information
7.10.2 Komipharm Business Overview
7.10.3 Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.10.5 Komipharm Recent Development
7.11 Agrovet
7.11.1 Agrovet Company Information
7.11.2 Agrovet Business Overview
7.11.3 Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.11.4 Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.11.5 Agrovet Recent Development
7.12 Bioveta
7.12.1 Bioveta Company Information
7.12.2 Bioveta Business Overview
7.12.3 Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.12.4 Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.12.5 Bioveta Recent Development
7.13 Jinyu
7.13.1 Jinyu Company Information
7.13.2 Jinyu Business Overview
7.13.3 Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.13.4 Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.13.5 Jinyu Recent Development
7.14 Phibro Animal Health
7.14.1 Phibro Animal Health Company Information
7.14.2 Phibro Animal Health Business Overview
7.14.3 Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.14.4 Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.14.5 Phibro Animal Health Recent Development
7.15 Tiankang
7.15.1 Tiankang Company Information
7.15.2 Tiankang Business Overview
7.15.3 Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.15.4 Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.15.5 Tiankang Recent Development
7.16 Zoetis
7.16.1 Zoetis Company Information
7.16.2 Zoetis Business Overview
7.16.3 Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.16.4 Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.16.5 Zoetis Recent Development
7.17 Yongshun Biological
7.17.1 Yongshun Biological Company Information
7.17.2 Yongshun Biological Business Overview
7.17.3 Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.17.4 Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.17.5 Yongshun Biological Recent Development
7.18 Pulike Biological
7.18.1 Pulike Biological Company Information
7.18.2 Pulike Biological Business Overview
7.18.3 Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Revenue and Gross Margin (2020-2025)
7.18.4 Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Products Offered
7.18.5 Pulike Biological Recent Development
8 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Manufacturing Cost Analysis
8.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine
8.4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors List
9.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Customers
10 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Dynamics
10.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Trends
10.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Drivers
10.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Challenges
10.4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
List of Tables
Table 1. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) by Region (2020-2025)
Table 5. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2020-2025)
Table 6. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Region (2020-2025)
Table 8. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Forecast by Region (2026-2031)
Table 9. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share Forecast by Region (2026-2031)
Table 12. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (K Dose) & (2020-2025)
Table 13. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Type (2020-2025)
Table 14. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Type (US$/Dose) & (2020-2025)
Table 16. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (K Dose) & (2026-2031)
Table 17. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Type (US$/Dose) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (K Dose) & (2020-2025)
Table 21. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Application (2020-2025)
Table 22. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Application (US$/Dose) & (2020-2025)
Table 24. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (K Dose) & (2026-2031)
Table 25. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price by Application (US$/Dose) & (2026-2031)
Table 27. New Sources of Growth in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Application
Table 28. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (K Dose) & (2020-2025)
Table 29. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Company (2020-2025)
Table 30. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Company (2020-2025)
Table 32. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine as of 2024)
Table 33. Global Market Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Company (US$/Dose) & (2020-2025)
Table 34. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Product Type & Application
Table 36. Global Key Manufacturers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025) & (K Dose)
Table 39. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Company (2020-2025)
Table 40. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Company (2020-2025)
Table 42. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025) & (K Dose)
Table 43. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2020-2025)
Table 44. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025) & (K Dose)
Table 45. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2020-2025)
Table 46. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025) & (K Dose)
Table 47. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Company (2020-2025)
Table 48. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Company (2020-2025)
Table 50. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025) & (K Dose)
Table 51. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2020-2025)
Table 52. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025) & (K Dose)
Table 53. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2020-2025)
Table 54. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025) & (K Dose)
Table 55. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Company (2020-2025)
Table 56. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Company (2020-2025)
Table 58. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025) & (K Dose)
Table 59. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2020-2025)
Table 60. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025) & (K Dose)
Table 61. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2020-2025)
Table 62. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Company (2020-2025) & (K Dose)
Table 63. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Company (2020-2025)
Table 64. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Company (2020-2025)
Table 66. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Type (2020-2025) & (K Dose)
Table 67. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type (2020-2025)
Table 68. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Application (2020-2025) & (K Dose)
Table 69. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application (2020-2025)
Table 70. China Animal Husbandry Co., Ltd. Company Information
Table 71. China Animal Husbandry Co., Ltd. Description and Business Overview
Table 72. China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 73. China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 74. China Animal Husbandry Co., Ltd. Recent Development
Table 75. Boehringer Ingelheim Company Information
Table 76. Boehringer Ingelheim Description and Business Overview
Table 77. Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 78. Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 79. Boehringer Ingelheim Recent Development
Table 80. MSD Animal Health Company Information
Table 81. MSD Animal Health Description and Business Overview
Table 82. MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 83. MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 84. MSD Animal Health Recent Development
Table 85. Sinopharm Animal Health Company Information
Table 86. Sinopharm Animal Health Description and Business Overview
Table 87. Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 88. Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 89. Sinopharm Animal Health Recent Development
Table 90. Ceva Company Information
Table 91. Ceva Description and Business Overview
Table 92. Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 93. Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 94. Ceva Recent Development
Table 95. Ruipu Biological Company Information
Table 96. Ruipu Biological Description and Business Overview
Table 97. Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 98. Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 99. Ruipu Biological Recent Development
Table 100. Qilu Animal Health Company Information
Table 101. Qilu Animal Health Description and Business Overview
Table 102. Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 103. Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 104. Qilu Animal Health Recent Development
Table 105. Dahuanong Company Information
Table 106. Dahuanong Description and Business Overview
Table 107. Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 108. Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 109. Dahuanong Recent Development
Table 110. CAVAC Company Information
Table 111. CAVAC Description and Business Overview
Table 112. CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 113. CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 114. CAVAC Recent Development
Table 115. Komipharm Company Information
Table 116. Komipharm Description and Business Overview
Table 117. Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 118. Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 119. Komipharm Recent Development
Table 120. Agrovet Company Information
Table 121. Agrovet Description and Business Overview
Table 122. Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 123. Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 124. Agrovet Recent Development
Table 125. Bioveta Company Information
Table 126. Bioveta Description and Business Overview
Table 127. Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 128. Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 129. Bioveta Recent Development
Table 130. Jinyu Company Information
Table 131. Jinyu Description and Business Overview
Table 132. Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 133. Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 134. Jinyu Recent Development
Table 135. Phibro Animal Health Company Information
Table 136. Phibro Animal Health Description and Business Overview
Table 137. Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 138. Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 139. Phibro Animal Health Recent Development
Table 140. Tiankang Company Information
Table 141. Tiankang Description and Business Overview
Table 142. Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 143. Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 144. Tiankang Recent Development
Table 145. Zoetis Company Information
Table 146. Zoetis Description and Business Overview
Table 147. Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 148. Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 149. Zoetis Recent Development
Table 150. Yongshun Biological Company Information
Table 151. Yongshun Biological Description and Business Overview
Table 152. Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 153. Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 154. Yongshun Biological Recent Development
Table 155. Pulike Biological Company Information
Table 156. Pulike Biological Description and Business Overview
Table 157. Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 158. Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product
Table 159. Pulike Biological Recent Development
Table 160. Production Base and Market Concentration Rate of Raw Material
Table 161. Key Suppliers of Raw Materials
Table 162. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors List
Table 163. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Customers List
Table 164. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Trends
Table 165. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Drivers
Table 166. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Challenges
Table 167. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Picture
Figure 2. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Type in 2024 & 2031
Figure 4. Live vaccines Product Picture
Figure 5. Inactivated vaccines Product Picture
Figure 6. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 7. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Application in 2024 & 2031
Figure 8. Government bidding Examples
Figure 9. Market sales Examples
Figure 10. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Growth Rate (2020-2031) & (US$ Million)
Figure 12. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)
Figure 13. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Price Trends Growth Rate (2020-2031) & (US$/Dose)
Figure 14. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Report Years Considered
Figure 15. Global Market Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 16. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Market Share by Region: 2020 VS 2024
Figure 17. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)
Figure 19. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)
Figure 21. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)
Figure 23. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (K Dose) Growth Rate (2020-2031)
Figure 25. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Type (2020-2025)
Figure 26. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Type (2026-2031)
Figure 27. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Type (2026-2031)
Figure 28. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Application (2020-2025)
Figure 29. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Growth Rate by Application in 2020 & 2024
Figure 30. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Application (2026-2031)
Figure 31. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Application (2026-2031)
Figure 32. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Share by Company (2024)
Figure 33. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Company (2024)
Figure 34. Global 5 Largest Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Players Market Share by Revenue in Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine: 2020 & 2024
Figure 35. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 36. Manufacturing Cost Structure of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine
Figure 37. Manufacturing Process Analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine
Figure 38. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industrial Chain
Figure 39. Channels of Distribution (Direct Vs Distribution)
Figure 40. Distributors Profiles
Figure 41. Bottom-up and Top-down Approaches for This Report
Figure 42. Data Triangulation
Figure 43. Key Executives Interviewed
